Printer Friendly

GENova Biotherapeutics signs collaboration agreement with Bridge Bioresearch.

GENova Biotherapeutics Inc. (New York, NY) has signed a collaboration agreement with Bridge Bioresearch Plc., an international drug development and discovery company that focuses on metabolic disorders. The two biotechnology drug acquisition companies plan to leverage each others' scientific findings and industry contacts for mutual gain.

GENova's business solely focuses on cancer cures, while Bridge BioResearch is geared at acquiring drug targets for Obesity and Type 2 Diabetes. Through the collaboration agreement, the two companies will partner to share research results and their global contacts with research organizations and pharmaceutical companies. They will also examine their findings to gain insight into the links between their respective fields of oncology and obesity, as cancer and obesity are both maladies that can be blamed on lifestyle choices.

"By collaborating with Bridge BioResearch, we will gain access to their excellent network of high quality research labs and universities around the world, as well as their well-established distribution channels," says Aaron Whiteman, CEO for GENova. "We are confident that through this collaboration, we will gain access to the latest and greatest in developmental cancer drugs to perpetuate our acquisition pipeline, as well as secure reliable distribution channels for our out-licensing objectives."

"Furthermore, through this collaboration, we will exchange our scientific findings to gain insight into the links between obesity and cancer, as many findings suggest that one of the main factors in cancer development is lifestyle choices, including unhealthy diet," says Whiteman.

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants.

GENova is positioning itself as a leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers.

GENova Biotherapeutics, Inc.

www.genovabio.com

Bridge BioResearch Plc

www.bridgebioresearch.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Words:347
Previous Article:Appeals Court affirms patent infringement rulings against Roche's peg-EPO product.
Next Article:RZN Nutraceuticals receives United States Patent and Trademark Office notice of allowance for proprietary HerbaZorb absorption and delivery.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters